Foghorn Stock Plunges After a Patient’s Death. Analysts Say It’s Still a Buy.
Text size The pause on Foghorn's study is only temporary, analysts say. Bogdan Hoda/Dreamstime Foghorn Therapeutics ...
Read moreText size The pause on Foghorn's study is only temporary, analysts say. Bogdan Hoda/Dreamstime Foghorn Therapeutics ...
Read moreEver since Medicare proposed to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm, the agency ...
Read more© 2022 TheDailyStock.News